Date: 2013-03-06
Type of information: R&D agreement
Compound: laminin-based in-vitro cell culture matrices
Company: Roche (Switzerland) BioLamina (Sweden)
Therapeutic area: Regenerative medicine
Type agreement: R&D
Action mechanism:
Disease:
Details: Roche and BioLamina have announced the signing of a research and development agreement to jointly develop new cell culture systems for various applications, including stem cell research. The collaboration will focus on assessing laminin-based in-vitro cell culture matrices offering highly physiological microenvironments for living cells. Under the terms of the agreement Roche will provide R&D funding and scientific expertise to BioLamina.
BioLamina commercializes innovations based on recombinant laminins developed by Professor Karl Tryggvason at the Karolinska Institute. These proteins are located in the extracellular matrix providing the stability essential for cell growth and behaviour. The use of laminins provides solutions to technical problems confronting stem cell culture. When cell culture dishes are coated with biologically relevant human recombinant laminins, many primary cells, including stem cells, feel comfortable and do not change their phenotype. In principle, this allows infinite culture of stem cells and other primary cell types in completely defined environments in vitro.
Financial terms: Financial details were not disclosed.
Latest news:
